Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus R-CHOP versus placebo plus R-CHOP in untreated MCD-subtype DLBCL
CTR20220735Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Innovent Biologics. Started Nov 2022; status: active.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20220735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220735.